Serac Imaging Systems Ltd. is seeing encouraging results from ongoing trials at three sites, which are comparing its Seracam portable hybrid gamma-optical camera for medical imaging to standard of care nuclear medicine imaging, Mark Rosser, CEO of the company, told BioWorld.

Quest Diagnostics Inc. agreed to purchase Canadian laboratory testing giant Lifelabs Inc. from the Ontario Municipal Employees Retirement System for US$985 million (CA$1.35 billion), including debt, in a deal expected to close by the end of the year. Quest projects that Lifelabs, which will retain its brand, headquarters and management, will contribute US$710 million in the first 12 months after closing.

By combining both tumor diagnosis and treatment in entities such as fluorescent probes, theranostic represents a new avenue in the development of selective, safe and low-risk resistance strategies.

Syntheticmr AB received CE marking for its next-generation brain imaging solution, SyMRI Neuro. The company hopes that version 15 of its SyMRI software, which provides quantitative data, automatic tissue segmentation and adjustable contrast weighted images from a scan, will transform diagnostic imaging.

In the first patenting to have been published in the name of Lo Biosciences Inc., the company’s co-founder and CEO Sasank Vemulapati seeks further protection for their development of a device and method that helps eliminate time, distance, and cost as barriers between patients and their next blood test, by allowing patients to collect laboratory quality blood samples at home without the assistance of any health care professionals.

“Do dreams predict the future?” Abidemi Otaiku asked his audience at the 10th Congress of the European Academy of Neurology, currently being held in Helsinki. Most audience members, being hard-boiled scientists, did not believe they did. But Otaiku, whose work won the award for best clinical abstract at the conference, presented data indicating that in some cases, they can.

A new non-invasive device which enables women to test themselves at home for signs of the cancer-causing human papillomavirus strains in menstrual blood, has been developed with support from the Venture Builder Incubator at the University of Edinburgh.

Nexsen Biotech Pty Ltd. developed a rapid diagnostic test for Group B Streptococcus, a highly prevalent and potentially fatal bacteria that is the single largest maternal health problem faced by pregnant mothers.

Hypoxia, a hallmark of the tumor microenvironment (TME), promotes malignant progression and resistance to chemotherapy and radiotherapy and hence, should be delimitated before treatment initiation. 

Sometimes a court cites long-standing precedent in deciding how to handle a case, but the U.S. Court of Appeals for the Federal Circuit leveraged a decision it rendered only last year in deciding a patent case between Apple Inc., and Omni Medsci Inc.